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Abstract  
Introduction: Gastric cancer is one of the major causes of cancer related deaths, but data from sub-Saharan Africa are very scanty. The cancer 
genome atlas (TCGA) initiative confirmed Epstein-Barr virus (EBV) related cancer as a distinct subtype, and we set out to look for serological 
evidence of its role in a sub-Saharan African patient group. Methods: We used stored serum samples obtained from a gastric cancer case-control 
study conducted between 2010 and 2012 in Lusaka, Zambia. A total of 147 patients were included with 51 gastric adenocarcinoma cases and 96 
age and sex matched controls. The presence of antibodies to EBV nuclear antigen-1 (EBNA-1) and early antigen (EA) was determined using 
commercially available ELISA kits. Data were analysed in STATA Stata Corp, College Station TX. Results: Over 90% of all the samples analysed 
were positive for antibodies to EBNA-1. The presence of antibodies to EBV EA was significantly higher in gastric cancer cases than in controls, (OR 
4.38; 95% CI 1.53-13.06, P=0.0027), with an attributable risk of 23%. HIV infection was also associated with EBV EA seroprevalence (OR 10.97; 
95% CI 2.26 -13.06, P=0.001) but not EBNA-1 (OR 0.81; 95% CI 0.10 -38.75, P=0.596). There was no association of EBV infection with age 
below 45 years, Helicobacter pylori infection, intestinal metaplasia, gastric atrophy or inflammation. Conclusion: We therefore conclude that EBV 
exposure is common among Zambian adults and that EBV EA seropositivity is associated with gastric cancer and HIV infection, but not 
premalignant lesions. 
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Introduction 
 
Gastric cancer is one of the major causes of cancer related deaths 
globally [1]. The burden of cancer related health problems is 
increasing in Africa, although it continues to receive relatively low 
public health priority [2]. Gastric cancer data from Sub-Saharan 
Africa are scarce [3] and there is an urgent need to begin collecting 
these data in order to understand the risk factors. There is an 
increase in the incidence of gastric cancer in sub-Saharan countries 
such as Uganda [4] in contrast with the reported decline in 
developed countries [5]. Estimates of the epidemiology of gastric 
cancer in Zambia also show an increase in the number of cases 
especially among young adults. It however, remains unclear if this is 
a real increase or just a reflection of improving awareness and 
availability of better diagnostic facilities. 
  
Epstein-Barr virus (EBV) is a DNA oncogenic herpes virus present in 
about 90% of the global adult population [6]. It is associated with 
nasopharyngeal and gastric cancers, follicular dendritic cell 
tumors/sarcomas, Burkitt’s lymphoma, lymphomatoid 
granulomatosis, pyothorax-associated lymphoma and Human 
Immunodeficiency Virus (HIV) associated conditions such as hairy 
leukoplakia and central nervous system lymphomas [7]. The Cancer 
Genome Atlas (TCGA) project recently characterized gastric 
adenocarcinoma into four major subtypes: EBV-positive tumors, 
microsatellite unstable tumors, genomically stable tumors, and 
tumors with chromosomal instability [10]. There is evidence that up 
to 9% of gastric cancer is attributed to EBV infection [8,9]. The 
analysis however, did not include samples from indigenous African 
subjects nor was the influence of Human Immunodeficiency virus 
(HIV) infection on the molecular characterization of gastric cancer 
considered. As a result the distribution of TCGA subtypes in sub-
Saharan Africa is not very clear. 
  
Gastric cancer in Zambia presents at younger ages than in Europe 
or North America [11]. It is not known how much EBV infection 
influences the development of gastric cancer in these young adults. 
Recent data from the USA suggest there has been an increase in 
the occurrence of non-cardia gastric cancer among young adults 
[12]. The interaction between HIV infection and EBV in gastric 
cancer development has not been described, although it has been 
reported that HIV infection increases the risk for EBV acquisition in 
Zambian children [13] and there is evidence of a higher EBV 
replication in HIV infected compared to uninfected children [14]. 
Higher loads of EBV DNA have also been reported in HIV infected 
individuals. In addition, HIV infected patients are at an increased 
risk of developing cancers with a known infectious cause [15] and it 
is uncertain if this is true for EBV positive gastric cancer. In this 
study, we evaluated the association between gastric cancer and EBV 
infection in Zambian adults using stored samples collected from a 
previous case-control study [16]. We evaluated the presence of 
antibodies to EBV nuclear antigen-1 (EBNA-1) and early antigens 
(EA), using enzyme-linked immunosorbent assay (ELISA). 
Antibodies against EBNA-1 are usually not detected until 90 days 
after an acute infection [6] and may persist for life [17]. EA 
antibodies are produced during the early phase of lytic replication 
and may be present in up to 80% of actively infected individuals 
[6]. 
  
  
Methods 
 
This was a retrospective analysis of stored serum samples. The 
samples were collected during a case-control study on gastric 
adenocarcinoma conducted at the University Teaching Hospital 
(UTH) in Lusaka, between November 2010 and January 2012 [16]. 
UTH is the largest referral hospital in Zambia attending to patients 
from all parts of the country. In this study, patients referred to the 
unit for diagnostic upper gastrointestinal endoscopy were 
considered for enrolment. Those willing to participate signed 
consent forms and were enrolled either as cases or controls. Gastric 
biopsies were obtained from all lesions suspected of being 
malignant. Cases were defined as patients with histologically 
confirmed gastric adenocarcinoma, while controls were age and sex 
matched patients with dyspeptic symptoms but no evidence of 
gastric cancer. Biopsies for histopathology were taken from the 
controls as follows, two each from the cardia, body and antrum. 
Patients with gastric Kaposi’s sarcoma or lymphoma were excluded. 
51 cases and 96 controls were studied. Blood was taken from study 
participants and serum was extracted and stored at negative 80 o C 
within our laboratories at UTH. The samples were clearly labelled 
with the date of collection and identification (ID) number. Ethical 
approval was obtained from the University of Zambia Biomedical 
and Ethics Committee (reference number 009-08-13). 
  
Laboratory analysis 
  
All the stored serum samples were retrieved although two samples 
(1 case and 1 control) were insufficient for analysis. Serum was 
then allowed to thaw to room temperature. Following the 
manufacturer’s instructions, we used Platelia, EB-NA-1 IgG for 
qualitative determination of IgG antibodies to EBNA-1 (Trinity 
Biotech, Wicklow, Ireland), and Platelia, EBV-EA-D IgG (Trinity 
Biotech, Wicklow, Ireland) for qualitative determination of IgG 
antibodies to EA. The Immune Status Ratio (ISR) was calculated by 
dividing the optical density for each specimen by the cut-off 
calibrator value. The assays were all validated as advised by the 
manufacturer. VK and KZ carried out the ELISAs and one full plate 
was repeated to confirm the consistency of the results. ISR values 
of less than 0.90 were considered negative, those between 0.91 and 
1.09 considered equivocal and those above 1.10 were declared 
positive. Equivocal results were not included in the final analysis. 
  
Statistical analysis 
  
We used STATA 13 (Stata Corp, College Station TX) to analyse the 
data. For continuous variables showing a non- Gaussian distribution, 
the Kruskal-Wallis test was used to compare the two groups. For 
categorical variables, the Fisher’s exact test was used. Odds Ratios 
with 95% confidence intervals, and two sided P values were derived 
to define the frequency of risk factors in cases and controls. 
Probability values less than 0.05 were considered statistically 
significant. Stepwise logistic regression was used to assess the 
relative contributions of different exposure variables to the risk of 
gastric cancer. 
  
  
Results 
 
A total of 147 serum samples (51 cases and 96 controls) were 
retrieved. Three cases had equivocal results, one for EBNA-1 and 
three for EA. One case was equivocal both for EBNA-1 and EA. 
Among the controls, two were equivocal for EA and one for EBNA-1. 
Serum samples with equivocal results were excluded from the final 
results. Therefore, when analysing for EBV antibodies, 48 cases and 
93 controls were used. The baseline characteristics of the two 
samples were similar, with the exception of body mass index, which 
was significantly lower in gastric cancer patients (Table 1). 
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EBNA -1 and EA antibody expression in cases and controls 
  
92.9 % of all the patients (both cases and controls) were positive 
for antibodies to EBNA-1, and there was minimal difference between 
cases and controls (Table 2). We compared seropositivity to EBNA-1 
and EA between cases and controls and found that the proportion of 
gastric cancer patients with positive EA was significantly higher than 
in controls (Table 2). The attributable risk of gastric cancer in 
patients with positive EA antibodies was 22.5 %. The group with 
evidence of past infection but no reactivation was the least likely to 
have gastric cancer, and the group with evidence of current 
infection was the most likely to have gastric cancer (Table 3). 
  
Risk factors for EBV in both patient groups 
  
We then analysed the association of antibodies to EBV with probable 
risk factors (Table 4). None of the factors considered showed any 
association with antibodies to EBNA-1 (Table 4). 90% of the HIV 
infected patients and 92% of the HIV negative patients were 
positive for EBNA-1, with no significant difference between the two. 
In contrast, 60% of those with HIV infection were positive for EA 
compared to 12% of the HIV uninfected patients (Odds ratio 10.97; 
95% CI 2.26 to 57.26, P=0.001; Table 4). EBV antibodies were not 
associated with gastric inflammation (acute or chronic), low 
pepsinogen 1 to 2 ratio or intestinal metaplasia. 
  
EBV anti-early antigen seropositivity by anatomical site and 
histological type 
  
We analysed the anatomical sites of the tumour as determined at 
endoscopy: 13% were in the cardia, 23% in the body, 52% in the 
antrum and 12% were in more than one site. There was no 
association between the site of the tumour and the presence of EBV 
EA antibodies (data not shown, P=0.66). We also considered the 
type of gastric cancer, using the Lauren classification. Among the 
patients included in this analysis, 81% had intestinal type, 13% had 
diffuse type, and 4% had mixed type of gastric adenocarcinoma. 
The classification for one tumour (2%) was not available. There was 
no association between the type of tumour and the presence of EBV 
EA antibodies (data not shown, P=0.52). 
  
  
Discussion 
 
The development of gastric cancer in young Zambian adults is not 
well described. We set out to investigate the association between 
gastric cancer and EBV infection by measuring antibodies to EBNA-1 
and EA in gastric cancer patients with age and sex matched 
controls. We found an association with antibodies to EA but not to 
EBNA-1. We also found that HIV infection itself was a risk factor for 
EA seropositivity. Gastric cancer is one of the major gastrointestinal 
cancers diagnosed in Zambia and the prognosis tends to be very 
poor with significant mortality at one year. [18] We recently 
completed a retrospective audit of endoscopy records going back 
almost four decades. The findings showed that the occurrence of 
gastric cancer is increasing in young adults, but not in older 
patients. This is in line with reports from the USA which also showed 
an increase in non cardia gastric cancer incidence among whites 
below the age of 40 years, emphasising that it is important to define 
independent trends in cancer subtypes which may be responding to 
differential exposures [12]. The diagnosis of gastric cancer in poor 
resource countries such as Zambia remains a challenge due to 
inadequate diagnostic facilities. It is likely that the burden of gastric 
cancer in this region remains under estimated. EBV is an almost 
ubiquitous infection globally resulting in clinically significant disease 
in a few individuals. EBV associated gastric tumours tend to confer 
better patients outcomes than those not associated with EBV [19]. 
It is not clear how much influence EBV infection has on the 
development of gastric cancer in Zambia. The TCGA consortium 
analysis confirms the importance of EBV in gastric cancer, but 
despite the well-known high prevalence of EBV in sub-Saharan 
Africa, very little work has been done. To our knowledge, this was 
the first study looking at the association of EBV infection with 
gastric cancer in Zambia. We used ELISA to determine the presence 
of antibodies to EBNA-1 and EA. EBNA-1 develops much later during 
the course of an infection and can persist for life. However, EBNA-1 
antibodies may be undetectable in the sera of up to 5% healthy 
individuals with past exposure to EBV [20]. 
 
In our study, 90% of the cases’ and 95% of the controls’ sera was 
positive for anti-EBNA-1 without any significant difference between 
the groups. There have been reports of anti-EBNA-1 loss during 
immunosuppression, [20] but we found no loss of anti-EBNA-1 in 
HIV infection. EA signifies EBV recent infection or reactivation. It is 
a transient antibody and can disappear with 3 to 4 months of 
infection or reactivation. It is not very clear how many transient 
phases of reactivation EBV infected persons have during their 
lifetime, as there are no distinctive clinical symptoms. We found that 
antibodies to EA were significantly higher in gastric cancer patients, 
with an attributable risk of 21.7%. This suggests that EBV continues 
replicating after the development of gastric cancer, findings that 
have also been suggested by other investigators [8,21]. It is yet to 
be established whether EBV reactivation is the one that triggers 
gastric carcinogenesis or the changes associated with gastric 
carcinogenesis trigger the reactivation of previously latent virus. 
Interpretation of antibodies to EA should be cautious, as they are 
only present in about 80% of affected individuals. There is currently 
no consensus on the threshold titres of EA for signifying EBV re-
activation. There have been reports of an interrelationship 
between Helicobacter pylori (H.pylori) infection and EBV. Lima et al 
reported finding H.pylori infection in all EBV positive gastric 
tumours. [22] Our study did not demonstrate any such association, 
as there was no significant difference in EBV seropositivity between 
patients with and without antibodies to H.pylori infection. The 
incidence of EBV associated gastric cancer tends to decrease with 
advancing age. We found no difference in EBV antibodies between 
older and younger patients. Some investigators have reported an 
association between EBV infection and gastric premalignant lesions 
[23]. While others have failed to demonstrate this [24] Schetter et 
al suggested that EBV reactivation occurs as an early phase of 
gastric carcinogenesis [23]. We found no evidence of an association 
between gastric intestinal metaplasia and either EBNA-1 or EA 
antibodies. There is a need to further explore the role of EBV 
infection in gastric malignancy as identification of the point at which 
it plays a role might suggest opportunities for prevention. We found 
no evidence that EBV EA antibodies vary by tumour site: cardia, 
body or antrum. The TCGA project identified a preponderance of 
EBV associated tumours in the body [10]. van Beek J and others 
found that the EBV associate tumours were more in the proximal 
regions of the stomach [25]. While our sample size is limited, our 
findings do not support an association between EBV with any 
particular site. We now have evidence that most of gastric 
adenocarcinoma in Zambia is of the intestinal type. Again, we found 
no evidence of an association between the Lauren classification and 
EBV infection. We recognize the fact that using serology to assess 
the association between gastric cancer and EBV infection is not 
optimal, but we have identified an important association and our 
data suggest that a high proportion of Zambian cancers could be 
EBV-related (population attributable fraction 23%). Further 
information from in-situ hybridization or PCR would give additional 
information as to the activation or latency of any virus present. This 
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study has demonstrated the urgent need for more gastric cancer 
research in sub-Saharan Africa, a region heavily affected by HIV 
infection. The role of HIV infection and its interaction with other 
viruses on the development of either premalignant lesions or gastric 
cancer may be different here to the role played in other 
geographical settings. 
  
  
Conclusion 
 
Serological response to Epstein-Barr virus early antigen is associated 
with gastric cancer and HIV infection. This association does not 
apply to gastric premalignant lesions. 
 
What is known about this topic 
 
• Gastric cancer is one of the leading causes of cancer related 
mortality and 9% of all the cases can be attributed to Epstein-
Barr virus (EBV) infection. There is an increase in gastric 
cancer diagnosis among Zambians less than 60 years, and the 
age at first diagnosis is lower than expected. The occurrence of 
gastric cancer in these young adults cannot be entirely 
attributed to a young population structure. 
 
What this study adds 
 
• This study has showed that the occurrence of gastric cancer in 
Zambia is associated with antibodies to EBV early antigens but 
not EBV nuclear antigen-1. The results also suggest an 
influence of EBV re-activation on gastric cancer carcinogenesis 
in Zambia. An association between EBV early antigens and HIV 
infection has been demonstrated. 
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Table 1: Basic demographic characteristics of cases and controls showing that the two groups were 
comparable 
  Cases, n=51 
n (%) 
Controls, n=96 
n(%) 
P 
Females 21(41.2) 48(51.6) 0.296 
Age in years:       
0.238 Less than 45 10(19.6) 27(29.0) 
Greater or equal to 45 41(80.4) 66(71.0) 
Educational achievement:       
0.207 None 10(19.6) 10(10.8) 
Primary or higher 41(80.4) 83(89.2) 
Occupation:       
0.833 None 10(19.6) 21(22.6) 
Formal or informal 41(80.4) 72(77.4) 
Body Mass Index (kg/m2)       
0.001 Less than 20 22(43.1) 16(17.2) 
More or equal to 20 29(56.9) 77(82.8) 
  
 
 
 
 
 
 
Table 2: the comparison of antibody expression between cases and controls. Its shows that there were significantly 
more patients with EBV-EA-D IgG among the gastric cancer cases 
  Cases n=48(%) Controls n=93(%) OR; 95% CI P 
EBV EB-NA-1 IgG 
positive 
43 (89.6) 88 (94.6) 0.49; 0.11 -2.26 0.3084 
EBV-EA-D 
IgGpositive 
14 (29.2) 8 (8.6) 4.38; 1.53 -13.06 0.0027 
 
 
 
 
Table 3: summary of the serological classification of cases and controls, with probable interpretations 
  Cases 
n (%) 
Controls 
n (%) 
OR; 95% CI P Possible 
interpretation 
EBNA-negative and 
EA-negative 
3 (6.2) 5 (5.4) 0.17(1.17-6.34) 1.000 No infection 
  
EBNA-negative and 
EA-positive 
2 (4.2) 0 (0) - 0.1143 Early primary infection 
EBNA-positive and 
EA-negative 
31 (64.6) 79 (86.0) 0.30(0.12-0.74) 0.0046 Past infection without 
reactivation 
EBNA-positive and 
EA-positive 
12 (25.0) 8 (8.6) 3.54(1.20-10.8) 0.0112 Probable viral 
reactivation 
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Table 4: probable risk factors for EBV infection in this group of patients, with HIV positive patients having 
significantly more individuals with EBV-EA-D IgG 
  EBV EB-NA-1 IgG 
n=141 
EBV-EA-D IgG 
n=141 
  OR; 95% CI P OR; 95% CI P 
Age below 45 years 1.05; 0.24 - 6.38 1.000 1.08; 0.32- 3.23 1.000 
HIV positive 0.81; 0.10 -38.75 0.596 10.97; 2.26 - 57.26 0.001 
H.pylori positive 0.57; 0.01 -4.37 1.000 1.67; 0.35 -15.95 0.738 
Low pep 1:2 ratio 2.10; 0.49 -12.6 0.362 1.30; 0.46 -3.62 0.637 
Low gastrin 0.34; 0.08 -1.76 0.111 0.18; 0.00 -1.27 0.126 
Intestinal metaplasia 0.33; 0.04 -4.19 0.238 0.74; 0.01 -6.61 1.000 
Acute or active 
inflammation 
0.43; 0.05 -3.48 0.374 0.28; 0.00 -2.40 0.427 
Chronic inactive 
inflammation 
0.62; 0.05 -4.63 0.692 0.42; 0.06 -2.36 0.284 
  
 
